Clinical Trial Update: Saracatinib in Treating Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Saracatinib in hormone-resistant/recurrent Stage IV prostate cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-04-01